Administration of nonanticoagulant heparin inhibits the loss of glycosaminoglycans from xenogeneic cardiac grafts and prolongs graft survival.
Stevens
R B
RB
Department of Surgery, University of Minnesota, Minneapolis.
Wang
Y L
YL
Kaji
H
H
Lloveras
J
J
Dalmasso
A
A
Bach
F H
FH
Rubinstein
P
P
Sutherland
D E
DE
Platt
J L
JL
D000818:Animals; D002478:Cells, Cultured; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism*; D006025:Glycosaminoglycans / Q000378:metabolism*; D006084:Graft Rejection / Q000517:prevention & control; D006085:Graft Survival / Q000502:physiology*; D006168:Guinea Pigs; D016027:Heart Transplantation / Q000502:physiology*; D006493:Heparin / Q000494:pharmacology*; D006497:Heparan Sulfate / Q000378:metabolism; D006801:Humans; D007700:Kinetics; D051381:Rats; D011917:Rats, Inbred Lew; D013552:Swine; D014183:Transplantation, Heterologous / Q000502:physiology*; D014185:Transplantation, Isogeneic / Q000502:physiology
D006025:Glycosaminoglycans; D006493:Heparin; D006497:Heparan Sulfate